The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

Hyderabad: Apollo Hospitals organised the STAT-2025 Conference on Stroke Thrombolysis and Thrombectomy with leading ...

This fellowship provides extensive training in: (1) Evaluation, diagnosis, and management of acute ischemic and hemorrhagic stroke, (2) Interpretation of neurovascular imaging including neurosonology, ...

Parkview Whitley Hospital and Parkview Kosciusko Hospital each recently received Primary Stroke Certification from The Joint Commission. Parkview Kosciusko Hospital received its initial certification ...

He continued, “The improved time to imaging compared to conventional MRI could facilitate quicker decision-making in acute stroke management, which could lead to the implementation of more ...

New research provides further evidence that thrombolysis benefits select patients with acute ischemic stroke up to 24 hours after symptom onset. In the HOPE trial, administration of intravenous ...

Children with sickle cell disease, a chronic hemolytic anemia, present with a wide variety of neurological syndromes, including ischemic and hemorrhagic stroke, transient ischemic attacks ...

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to the manufacturer. Genentech said in a press release that TNKase ...